Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 30S ribosomal subunit of Cutibacterium acnes (formerly Propionibacterium acnes) is a fundamental component of the bacterial translation apparatus, responsible for decoding genetic information from messenger RNA. It consists of the 16S ribosomal RNA and approximately 21 ribosomal proteins, which together coordinate the binding of transfer RNA and the initiation of protein synthesis. This subunit is a major pharmacological target for antibiotics used in the treatment of acne vulgaris, such as tetracyclines and aminoglycosides. These drugs typically bind to the decoding center of the 30S subunit, preventing the attachment of aminoacyl-tRNA and thereby halting bacterial growth. While C. acnes is a common skin commensal, its overproliferation and biofilm formation are central to the pathogenesis of inflammatory acne and various opportunistic infections. Recent structural studies have identified C. acnes-specific features of the 30S subunit, such as the presence of the bS22 protein, which may influence drug binding and selectivity. Sarecycline, a narrow-spectrum antibiotic, specifically targets this subunit with high affinity, offering a more selective approach compared to broad-spectrum tetracyclines. Therapeutic intervention targeting the 30S subunit must balance efficacy against the pathogen with the preservation of the host's commensal microbiome and the prevention of antibiotic resistance.
Inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit, specifically at the decoding center (A-site), which prevents the association of aminoacyl-tRNA with the mRNA-ribosome complex and halts the elongation of the polypeptide chain.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cutibacterium acnes 30S ribosomal subunit (C. acnes 30S subunit).